A bulk of the generic substitution going on right now is infringing on Reduce It patents and that hasn't stopped it. The market will not care about MND-2119 unless it is cheaper to dispense than gV. That is the total end of story. If it isn't cheaper, it simply will not get insurance coverage and you'll be told to take your 4 grams and be happy or pay for it out of your own pocket. What do you think most people, not invested in this company, will do?
News 
Market Data 
Discover 
AI
